High incidence of microsatellite instability and loss of heterozygosity in three loci in breast cancer patients receiving chemotherapy: a prospective study

BMC Cancer

Ulf Rannug⁴  Khaled H Al Qawasmeh¹  Mouied M Alashari²  Sabir Hussain¹  Mohammed Jaloudi¹  Mohammed A Khidhir³  Nasir Kamat⁴ 

[1]Department of Oncology and Hematology, Tawam Hospital, Abu Dhabi, UAE

[2]Department of Pathology, Tawam Hospital, Abu Dhabi, UAE

[3]Department of Genetics Research, Management of Natural Conservations, Abu Dhabi, UAE

[4]Department of Genetics, Microbiology and Toxicology, Stockholm University, Stockholm, Sweden

关键词: Loss of heterozygosity;    Mismatch repair;    Microsatellites;    Genetic instability;    Breast cancer;    Chemotherapy;   

Others  :  1080235
DOI  :  10.1186/1471-2407-12-373

 received in 2012-01-24, accepted in 2012-08-21,  发布年份 2012

【 摘 要 】

Background

The aim of the study was to evaluate potential chemotherapy-induced microsatellite instability, loss of heterozygosity, loss of expression in mismatch repair proteins and associations with clinical findings in breast cancer patients, especially resistance to chemotherapy and/or development of other tumors in the four years following chemotherapy treatment.

Methods

A comprehensive study of chemotherapy-related effects with a follow-up period of 48 months post treatment was conducted. A total of 369 peripheral blood samples were collected from 123 de novo breast cancer patients. Microsatellite instability and loss of heterozygosity in five commonly used marker loci (including Tp53-Alu of the tumor suppressor gene TP53) were analyzed in blood samples. Sampling was conducted on three occasions; 4–5 weeks prior to the first chemotherapy session (pre-treatment), to serve as a baseline, followed by two consecutive draws at 12 weeks intervals from the first collection. Mismatch repair protein expression was evaluated in cancer tissues using immunohistochemistry for three mismatch-repair related proteins.

Results

A total of 70.7% of the patients showed microsatellite instability for at least one locus, including 18.6% marked as high-positive and 52.1% as low-positive; 35.8% showed loss of heterozygosity in addition to microsatellite instability, while 29.3% exhibited microsatellite stability. The following incidence rates for microsatellite instability and loss of heterozygosity were detected: 39.1% positive for Tp53-Alu, 31.1% for locus Mfd41, and 25.3% for locus Mfd28. A higher occurrence of loss of heterozygosity was noted with alleles 399 and 404 of Tp53-Alu. The mismatch repair protein expression analysis showed that the chemotherapy caused a loss of 29.3% in hMLH1 expression, and 18.7% and 25.2% loss in hMSH2 and P53 expression, respectively. A strong correlation between low or deficient hMSH2 protein expression and occurrence of mismatch repair/loss of heterozygosity events in Mfd41, Tp53-Alu, and Mfd28 was evident. A significant association between mismatch repair/loss of heterozygosity and incidence of secondary tumors was also established.

Conclusion

Our results suggest that microsatellite instability, loss of heterozygosity, and deficiency in mismatch repair may serve as early prognostic factors for potential chemotherapy-related side effects in breast cancer patients.

【 授权许可】

   
2012 Kamat et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003, 21(5):897-906.
• [2]Leone G, Pagano L, Ben-Yehuda D, Voso MT: Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92(10):1389-1398.
• [3]Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, Lobelle JP, Larsimont D, et al.: Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003, 14(5):693-698.
• [4]Berger C, Trombert-Paviot B, Casagranda L, Mialou V, Frappaz D, Plantaz D, Collardeau-Frachon S, Freycon F: Second malignant neoplasms following childhood cancer: a study of a recent cohort (1987–2004) from the childhood cancer registry of the Rhone-Alpes region (ARCERRA) in France. Pediatr Hematol Oncol 2011, 28(5):364-379.
• [5]Ricci F, Tedeschi A, Montillo M, Morra E: Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's Macroglobulinemia. Mediterr J Hematol Infect Dis 2011, 3(1):e2011031.
• [6]Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, et al.: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer, The Cancer and Leukemia Group B. J Natl Cancer Inst 1998, 90(16):1205-1211.
• [7]Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, et al.: Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001, 19(12):3103-3110.
• [8]Leone G, Mele L, Pulsoni A, Equitani F, Pagano L: The incidence of secondary leukemias. Haematologica 1999, 84(10):937-945.
• [9]Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, et al.: Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 2011, 105(3):360-365.
• [10]Shi JY, Ren ZH, Jiao B, Xiao R, Yun HY, Chen B, Zhao WL, Zhu Q, Chen Z, Chen SJ: Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia. Int J Cancer 2011, 128(1):233-238.
• [11]Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS: Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001, 61(15):5723-5726.
• [12]Thornley I, Sutherland R, Wynn R, Nayar R, Sung L, Corpus G, Kiss T, Lipton J, Doyle J, Saunders F, et al.: Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood 2002, 99(7):2387-2396.
• [13]Abdel-Rahman WM: Genomic instability and carcinogenesis: an update. Curr Genomics 2008, 9(8):535-541.
• [14]McMurray CT: Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet 2010, 11(11):786-799.
• [15]Nobili S, Bruno L, Landini I, Napoli C, Bechi P, Tonelli F, Rubio CA, Mini E, Nesi G: Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 2011, 17(3):290-299.
• [16]Laurent-Puig P, Agostini J, Maley K: Colorectal oncogenesis. Bull Cancer 2011, 97(11):1311-1321.
• [17]Bellizzi AM, Frankel WL: Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009, 16(6):405-417.
• [18]Akoum R, Ghaoui A, Brihi E, Ghabash M, Hajjar N: Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation. Hered Cancer Clin Pract 2009, 7(1):10. BioMed Central Full Text
• [19]Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN: Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005, 4(3):255-265.
• [20]Nakagawa H, Lockman JC, Frankel WL, Hampel H, Steenblock K, Burgart LJ, Thibodeau SN, de la Chapelle A: Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res 2004, 64(14):4721-4727.
• [21]Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Yothers G, Allegra C, Moore MJ, Gallinger S, et al.: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011, 103(11):863-875.
• [22]Bastos DA, Ribeiro SC, de Freitas D, Hoff PM: Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. Ther Adv Med Oncol 2010, 2(4):261-272.
• [23]Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350(23):2343-2351.
• [24]Farias IL, Araujo MC, Farias JG, Rossato LV, Elsenbach LI, Dalmora SL, Flores NM, Durigon M, Cruz IB, Morsch VM, et al.: Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial. Evid Based Complement Alternat Med 2011, 2012:892182.
• [25]Mori M, Kida H, Morishita H, Goya S, Matsuoka H, Arai T, Osaki T, Tachibana I, Yamamoto S, Sakatani M, et al.: Microsatellite instability in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2001, 24(4):398-404.
• [26]Zavras AI, Pitiphat W, Wu T, Cartsos V, Lam A, Douglass CW, Diehl SR: Insulin-like growth factor II receptor gene-167 genotype increases the risk of oral squamous cell carcinoma in humans. Cancer Res 2003, 63(2):296-297.
• [27]Mrozek A, Petrowsky H, Sturm I, Kraus J, Hermann S, Hauptmann S, Lorenz M, Dorken B, Daniel PT: Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ 2003, 10(4):461-467.
• [28]Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, et al.: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997, 89(23):1758-1762.
• [29]Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58(22):5248-5257.
• [30]Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al.: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268.
• [31]Yu J, Mallon MA, Zhang W, Freimuth RR, Marsh S, Watson MA, Goodfellow PJ, McLeod HL: DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res 2006, 12(17):5104-5111.
• [32]EGAPP: Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11(1):35-41.
• [33]Bacher JW, Flanagan LA, Smalley RL, Nassif NA, Burgart LJ, Halberg RB, Megid WM, Thibodeau SN: Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers 2004, 20(4–5):237-250.
• [34]Fonseca FL, Sant Ana AV, Bendit I, Arias V, Costa LJ, Pinhal AA, del Giglio A: Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Res 2005, 7(1)):R28-R32.
• [35]Goel A, Nagasaka T, Hamelin R, Boland CR: An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 2010, 5(2):e9393.
• [36]Powierska-Czarny J, Miscicka-Sliwka D, Czarny J, Grzybowski T, Wozniak M, Drewa G, Czechowicz W, Sir J: Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system. Acta Biochim Pol 2003, 50(4):1195-1203.
• [37]Bener A, Honein G, Carter AO, Da'ar Z, Miller C, Dunn EV: The determinants of breast cancer screening behavior: a focus group study of women in the United Arab Emirates. Oncol Nurs Forum 2002, 29(9):E91-E98.
• [38]Ravichandran K, Al-Zahrani AS: Association of reproductive factors with the incidence of breast cancer in Gulf Cooperation Council countries. East Mediterr Health J 2009, 15(3):612-621.
• [39]Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J: Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997, 57(21):4749-4756.
• [40]Agresti A: categorical data analysis. 2nd edition. Wiley, New Jersey; 2002.
• [41]Viguera E, Canceill D, Ehrlich SD: Replication slippage involves DNA polymerase pausing and dissociation. EMBO J 2001, 20(10):2587-2595.
• [42]Golubov A, Yao Y, Maheshwari P, Bilichak A, Boyko A, Belzile F, Kovalchuk I: Microsatellite instability in Arabidopsis increases with plant development. Plant Physiol 2010, 154(3):1415-1427.
• [43]Campregher C, Scharl T, Nemeth M, Honeder C, Jascur T, Boland CR, Gasche C: The nucleotide composition of microsatellites impacts both replication fidelity and mismatch repair in human colorectal cells. Hum Mol Genet 2010, 19(13):2648-2657.
• [44]Kumar D, Abdulovic AL, Viberg J, Nilsson AK, Kunkel TA, Chabes A: Mechanisms of mutagenesis in vivo due to imbalanced dNTP pools. Nucleic Acids Res 2010, 39(4):1360-1371.
• [45]Matsuda T, Bebenek K, Masutani C, Hanaoka F, Kunkel TA: Low fidelity DNA synthesis by human DNA polymerase-eta. Nature 2000, 404(6781):1011-1013.
• [46]Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260(5109):812-816.
• [47]Lawes DA, Pearson T, Sengupta S, Boulos PB: The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer 2005, 93(4):472-477.
• [48]Narayan S, Roy D: Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2003, 2:41. BioMed Central Full Text
• [49]Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM: Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003, 63(13):3724-3728.
• [50]Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T, Kakudo K: Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 2002, 8(9):2890-2893.
• [51]Smeds J, Warnberg F, Norberg T, Nordgren H, Holmberg L, Bergh J: Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity. Acta Oncol 2005, 44(1):41-49.
• [52]Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, et al.: Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 2009, 15(10):3550-3556.
• [53]Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T: p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 2002, 8(5):1192-1195.
• [54]Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT: TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005, 26(10):1770-1773.
• [55]Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A: TP53 and gastric carcinoma: a review. Hum Mutat 2003, 21(3):258-270.
• [56]Langerod A, Zhao H, Borgan O, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007, 9(3):R30. BioMed Central Full Text
• [57]Berge EO, Knappskog S, Lillehaug JR, Lonning PE: Alterations of the retinoblastoma gene in metastatic breast cancer. Clin Exp Metastasis 2011, 28(3):319-326.